Sarepta Therapeutics’ (SRPT) Overweight Rating Reiterated at Piper Sandler

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “overweight” rating restated by Piper Sandler in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $205.00 price objective on the biotechnology company’s stock. Piper Sandler’s price objective would suggest a potential upside of 27.16% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Bank of America lifted their price objective on Sarepta Therapeutics from $166.00 to $213.00 and gave the company a “buy” rating in a research report on Friday, June 21st. Oppenheimer raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a research report on Tuesday, May 14th. Royal Bank of Canada lifted their price objective on Sarepta Therapeutics from $142.00 to $182.00 and gave the company a “sector perform” rating in a research report on Friday, June 21st. Barclays lifted their price objective on Sarepta Therapeutics from $185.00 to $226.00 and gave the company an “overweight” rating in a research report on Friday, June 21st. Finally, Morgan Stanley reissued an “overweight” rating and set a $165.00 price target on shares of Sarepta Therapeutics in a research report on Friday, June 21st. Five investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $187.72.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock traded up $3.21 during mid-day trading on Monday, hitting $161.21. 110,327 shares of the company were exchanged, compared to its average volume of 1,399,812. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The business’s 50 day simple moving average is $129.74 and its two-hundred day simple moving average is $122.66. The company has a market capitalization of $15.24 billion, a P/E ratio of 1,465.55 and a beta of 0.89. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The business’s revenue for the quarter was up 63.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.44) earnings per share. Analysts forecast that Sarepta Therapeutics will post 3.71 earnings per share for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the sale, the insider now owns 18,125 shares in the company, valued at $2,537,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Bilal Arif sold 7,859 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the completion of the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dallan Murray sold 3,635 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the transaction, the insider now directly owns 18,125 shares of the company’s stock, valued at $2,537,500. The disclosure for this sale can be found here. Insiders have sold 50,451 shares of company stock worth $8,086,386 over the last quarter. 7.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors have recently made changes to their positions in the stock. Mather Group LLC. bought a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $28,000. Riggs Asset Managment Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares during the last quarter. New Covenant Trust Company N.A. bought a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $32,000. Principal Securities Inc. bought a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $26,000. Finally, GAMMA Investing LLC grew its holdings in Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.